1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C1967016A423734985256F6A00830593
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-effectiveness-of-pharmaceutical-lifecycle-management-tactics?opendocument
18
19opendocument
203.239.87.20
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Sales and Marketing » New Product Development and Launch » Optimizing Product Portfolio » Lifecycle Management

Effectiveness of Pharmaceutical Lifecycle Management Tactics

DB Image

ID: 4864


Features:

Metrics, Graphics, Summary Matrix, Detailed Process Map


Pages/Slides: 54


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Study Overview

This survey-based benchmarking exchange was designed to understand how companies can extend and optimize the value of pharmaceutical products as they enter the late mature phase of the product life cycle. This study identifies those activities that have proven to be successful life cycle management techniques for the late mature phase. These tactics can help extend product life, find new markets and continue product growth.

Pharmaceutical, medical device and biotech companies can benefit from this 54-slide presentation on the most commonly utilized life cycle management strategies.

Key topics

  • Tactic Use - Frequency
  • Tactic Use - Success Rate
  • Months Gained
  • Incremental Revenues Gained
  • Considerations Before Use
  • Time Required for Success
  • Funds Required for Success
  • Challenges
  • Key Success Factors
  • Response Matrix

Key Findings
  • Successful lifecycle management tactics gained companies as much as 10 years of additional product life.
  • The average number of months gained by respondents using LCM strategies ranged from two to 78 months.
  • The top five most used tactics are also the top five most frequently successful tactics. Those are: new formulations, new indications, publication strategy, thought leaders and line extensions.
Methodology
This document is the result of a Best Practices, LLC project for a pharmaceutical Business Excellence Board client. It is based on the survey responses of 11 leading benchmark partners in the
pharmaceutical industry.

Industries Profiled:
Pharmaceutical; Chemical; Biotech; Health Care; Medical Device; Manufacturing; Consumer Products; Diagnostic


Companies Profiled:
Abbott Laboratories; Solvay America; Sanofi-Synthelabo Inc.; Pfizer; Ortho Biotech; Organon; Novartis; Eli Lilly and Company; IVAX; Baxter Healthcare; Bayer

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.